Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H11N3O3 |
| Molecular Weight | 281.2661 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1
InChI
InChIKey=KJONHKAYOJNZEC-UHFFFAOYSA-N
InChI=1S/C15H11N3O3/c19-14-9-16-15(10-4-2-1-3-5-10)12-8-11(18(20)21)6-7-13(12)17-14/h1-8H,9H2,(H,17,19)
| Molecular Formula | C15H11N3O3 |
| Molecular Weight | 281.2661 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.drugbank.ca/drugs/DB01595Curator's Comment: description was created based on several sources, including
https://www.drugs.com/mmx/nitrazepam.html | https://www.ncbi.nlm.nih.gov/pubmed/27685474 | https://www.ncbi.nlm.nih.gov/pubmed/12657414 | https://www.medicines.org.uk/emc/medicine/24136 | https://www.ncbi.nlm.nih.gov/pubmed/7861419
Sources: https://www.drugbank.ca/drugs/DB01595
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/mmx/nitrazepam.html | https://www.ncbi.nlm.nih.gov/pubmed/27685474 | https://www.ncbi.nlm.nih.gov/pubmed/12657414 | https://www.medicines.org.uk/emc/medicine/24136 | https://www.ncbi.nlm.nih.gov/pubmed/7861419
Nitrazepam (trade names: Alodorm, Apodorm, Arem, Mogadon, Nitrados, Nitrazadon, Nitrosun, Ormodon, Paxadorm, Remnos, and Somnite) is a hypnotic drug of the benzodiazepine class, indicated for the short-term relief of severe, disabling anxiety and insomnia. Nitrazepam has sedative and motor-impairing properties, as well as amnestic, anticonvulsant, and skeletal muscle relaxant effects. Nitrazepam is used to treat short-term sleeping problems (insomnia), namely difficulty falling asleep, frequent awakening, early awakening, or a combination of each. Nitrazepam is sometimes tried to treat epilepsy when other medications fail. It has been found to be more effective than clonazepam in the treatment of West syndrome, which is age-dependent epilepsy, affecting the very young. In uncontrolled studies, nitrazepam has shown effectiveness in infantile spasms and is sometimes considered when other anti-seizure drugs have failed. However, drowsiness, hypotonia, and most significantly tolerance to anti-seizure effects typically develop with long-term treatment, generally limiting Nitrazepam to acute seizure management. More common side effects may include: Central nervous system depression, including somnolence, dizziness, depressed mood, rage, violence, fatigue, ataxia, headache, vertigo, impairment of memory, impairment of motor functions, hangover feeling in the morning, slurred speech, decreased physical performance, numbed emotions, reduced alertness, muscle weakness, double vision, and inattention have been reported. Unpleasant dreams and rebound insomnia have also been reported. Nitrazepam is a long-acting benzodiazepine with an elimination half-life of 15–38 hours (mean elimination half-life 26 hours).
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7861419 |
38.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Insomin Approved UseUnknown |
|||
Sources: http://www.rlsnet.ru/tn_index_id_6300.htm |
Primary | Alodorm Approved UseUnknown |
||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Anemia in children with chronic kidney disease. | 2008-02 |
|
| Long-term stability of various drugs and metabolites in urine, and preventive measures against their decomposition with special attention to filtration sterilization. | 2008-01-30 |
|
| Comparison of molecularly imprinted solid-phase extraction (MISPE) with classical solid-phase extraction (SPE) for the detection of benzodiazepines in post-mortem hair samples. | 2008-01-15 |
|
| Solubility of selected derivatives of 1,4-benzodiazepin-2-one in solid dispersions in PEG 6000. | 2007-05-23 |
|
| The effect of placebo administration on the first-night effect in healthy young volunteers. | 2007-05-09 |
|
| Extraction and analysis of clonazepam and 7-aminoclonazepam in whole blood using a dual internal standard methodology. | 2007-03-02 |
|
| Surviving against all odds: analysis of 6 case studies of patients with cancer who followed the Gerson therapy. | 2007-03 |
|
| Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. | 2007-02 |
|
| Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam. | 2007-02 |
|
| Drug screening of preserved oral fluid by liquid chromatography-tandem mass spectrometry. | 2007-02 |
|
| Separation of 1,4-benzodiazepines by micellar elektrokinetic capillary chromatography. | 2007-01-10 |
|
| Neonatal anemia and hydrops fetalis after maternal mycophenolate mofetil use. | 2007-01 |
|
| Intrastrain variations in anxiolytic effect of nitrazepam in mice. | 2006-12-30 |
|
| Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature. | 2006-12 |
|
| Prospective study of first-choice topiramate therapy in newly diagnosed infantile spasms. | 2006-11-11 |
|
| Quantification of benzodiazepines in whole blood and serum. | 2006-11 |
|
| A survey of buprenorphine related deaths in Singapore. | 2006-10-16 |
|
| Detection of benzodiazepines in hair using ELISA and LC-ESI-MS-MS. | 2006-09 |
|
| Hypnosis for treatment of insomnia in school-age children: a retrospective chart review. | 2006-08-16 |
|
| Cross-sensitivity in a child with anticonvulsant hypersensitivity syndrome. | 2006-08-11 |
|
| Quality of life in patients with various Barrett's esophagus associated health states. | 2006-08-02 |
|
| Modeling cumulative dose and exposure duration provided insights regarding the associations between benzodiazepines and injuries. | 2006-04 |
|
| Extraction and analysis of flunitrazepam/7-aminoflunitrazepam in blood and urine by LC-PDA and GC-MS using butyl SPE columns. | 2006-03-10 |
|
| Streambed microstructure predicts evolution of development and life history mode in the plethodontid salamander Eurycea tynerensis. | 2006-03-02 |
|
| [Changes in the sale and use of flunitrazepam in Norway after 1999]. | 2006-02-23 |
|
| Antimicrobial proteins and polypeptides in pulmonary innate defence. | 2006-02-17 |
|
| Voltammetric behavior of nitrazepam and its determination in serum using liquid chromatography with redox mode dual-electrode detection. | 2006-01-15 |
|
| Anti-conflict effects of benzodiazepines in rhesus monkeys: relationship with therapeutic doses in humans and role of GABAA receptors. | 2006-01 |
|
| Primary care use of antipsychotic drugs: an audit and intervention study. | 2005-11-29 |
|
| Models of treatment with antipsychotics of the schizophrenic patients. | 2005-11 |
|
| Rapid in vivo Taxotere quantitative chemosensitivity response by 4.23 Tesla sodium MRI and histo-immunostaining features in N-Methyl-N-Nitrosourea induced breast tumors in rats. | 2005-08-03 |
|
| An analysis of epilepsy with chromosomal abnormalities. | 2005-08 |
|
| QT interval prolongation after sertraline overdose: a case report. | 2005-07-19 |
|
| [Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes]. | 2005-06 |
|
| The interaction of lipophilic drugs with intestinal fatty acid-binding protein. | 2005-05-06 |
|
| Determination of 14 benzodiazepines and hydroxy metabolites, zaleplon and zolpidem as tert-butyldimethylsilyl derivatives compared with other common silylating reagents in whole blood by gas chromatography-mass spectrometry. | 2005-04-25 |
|
| Patient perspectives: Tijuana cancer clinics in the post-NAFTA era. | 2005-03 |
|
| Sialorrhea: a review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease. | 2005-02 |
|
| Effect of antiepileptic drug polytherapy on crystalluria. | 2005-02 |
|
| Solid-phase extraction of methadone enantiomers and benzodiazepines in biological fluids by two polymeric cartridges for liquid chromatographic analysis. | 2005-01-25 |
|
| [West syndrome--new therapeutic approach]. | 2005-01-11 |
|
| Epilepsy in Wolf-Hirschhorn syndrome (4p-). | 2005-01 |
|
| Risk and benefit of drug use during pregnancy. | 2005 |
|
| [Benzodiazepine (clonazepam, nitrazepam, diazepam)]. | 2004-12 |
|
| Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. 1978. | 2004-12 |
|
| Nutrition and cancer: a review of the evidence for an anti-cancer diet. | 2004-10-20 |
|
| Clinical review: how to identify high-risk surgical patients. | 2004-10 |
|
| [Analysis of 7-aminonitrazepam in urine by trimethylsilyl derivatization-gas chromatography/mass spectrometry]. | 2002-09 |
|
| Depersonalization following nitrazepam withdrawal. | 1992-01-15 |
|
| Studies on the involvement of opioid mechanism in the locomotor effects of benzodiazepines in rats. | 1991-02 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mmx/nitrazepam.html
Oral, 5 or 10 mg at bedtime
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:35:59 GMT 2025
by
admin
on
Mon Mar 31 17:35:59 GMT 2025
|
| Record UNII |
9CLV70W7HS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QN05CD02
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
||
|
NCI_THESAURUS |
C1012
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
||
|
WHO-ATC |
N05CD02
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
||
|
DEA NO. |
2834
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB01595
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
1945
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
100000091767
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
2121
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
58775
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
m7931
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | Merck Index | ||
|
4506
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
C87674
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
Nitrazepam
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
CHEMBL13209
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
DTXSID5023372
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
D009567
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
146-22-5
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
NITRAZEPAM
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
9CLV70W7HS
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
NITRAZEPAM
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | Description: A yellow, crystalline powder; odourless or almost odourless. Solubility: Practically insoluble in water; slightly soluble in ethanol (~750 g/l) TS; very slightly soluble in ether R. Category: Sedative; hypnotic. Storage: Nitrazepam should be kept in a well-closed container, protected from light. Definition: Nitrazepam contains not less than 98.5% and not more than 101.0% of C15H11N3O3, calculated with reference to thedried substance. | ||
|
7581
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
SUB09318MIG
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | |||
|
7440
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY | RxNorm | ||
|
205-665-2
Created by
admin on Mon Mar 31 17:35:59 GMT 2025 , Edited by admin on Mon Mar 31 17:35:59 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |